Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Perrigo ships generic Mucinex extended-release; Valeant buys Obagi Medical Products; FDA advisory committee will discuss AERs; DXM legislation offered again; bill revived to allow Primatene Mist sales; Intercore will market MeliaLife products; more news In Brief.

You may also be interested in...



FDA Needs To Track Actions Built On Supplement AERs – GAO Report

A GAO report says FDA “may be able to expand” its use of supplement adverse event reports if it can track its use of the data to support actions it takes to protect consumers. The report makes five key recommendations for the agency to improve its approach to AERs.

In Brief

Plan B One-Step gets generic competition; legislation to restrict DXM introduced again; J&J agrees to reforms in settlement; China recants on MJN formula concerns; Buster line drives Hi-Tech Pharmacal OTC growth; Sabinsa awarded profits from infringed ForsLean trademark; more news In Brief.

Perrigo Sets Generic Mucinex Launch After Patent Claim Decision

The private labeler clears a Reckitt Benckiser legal hurdle and will launch generic Mucinex (guaifenesin) by April. Watson has filed ANDAs for three Mucinex products and could be a good strategic partner for Perrigo, an analyst suggests.

Topics

Related Companies

UsernamePublicRestriction

Register

PS106301

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel